AstraZeneca PLC — Regulatory Filings 2019

Dec 2, 2019

6-K 1 a3789v.htm BLOCK LISTING INTERIM REVIEW Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2019 Issuer Direct Corporation Blueprint

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of December 2019

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Block listing Interim Review

02 December 2019 15:00 GMT

Block Listing Six Monthly Return

Information provided on this form must be typed or printed electronically and provided to an ris .

Date: 2 December 2019

| Name
of applicant : — Name of
scheme: | | ASTRAZENECA
PLC — ASTRAZENECA
SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN;
ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012
SAVINGS-RELATED SHARE OPTION SCHEME | | |
| --- | --- | --- | --- | --- |
| Period
of return: | From: | 1 June
2019 | To: | 30
November 2019 |
| Balance
of unallotted securities under scheme(s) from previous
return: | | 1,248,036 | | |
| Plus: The amount by which the block scheme(s) has been
increased since the date of the last return (if any increase has
been applied for): | | 0 | | |
| Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G): | | 136,370 | | |
| Equals: Balance under scheme(s) not yet issued/allotted
at end of period: | | 1,111,666 | | |

| Name of
contact: | CAMILLA
JOHNSTONE |
| --- | --- |
| Telephone
number of contact: | 020
3749 5000 |

About AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @ AstraZeneca .

| Media
Relations — Gonzalo
Viña | | +44 203
749 5916 |
| --- | --- | --- |
| Rob
Skelding | Oncology | +44 203
749 5821 |
| Rebecca
Einhorn | Oncology | +1 301
518 4122 |
| Matt
Kent | BioPharmaceuticals | +44 203
749 5906 |
| Jennifer
Hursit | Other | +44
203 749 5762 |
| Christina Malmberg
Hägerstrand | Sweden | +46 8 552 53 106 |
| Michele
Meixell | US | +1 302
885 2677 |
| Investor
Relations | | |
| Thomas
Kudsk Larsen | | +44 203
749 5712 |
| Henry
Wheeler | Oncology | +44 203
749 5797 |
| Christer
Gruvris | BioPharmaceuticals
(Cardiovascular, Metabolism) | +44 203
749 5711 |
| Nick
Stone | BioPharmaceuticals
(Renal) Environmental, Social and Governance | +44 203
749 5716 |
| Josie
Afolabi | BioPharmaceuticals
(Respiratory) Other
medicines | +44 203
749 5631 |
| Craig
Marks | Finance Fixed
income | +44
7881 615 764 |
| Jennifer
Kretzmann | Corporate
access Retail
investors | +44 203
749 5824 |
| US
toll-free | | +1 866
381 72 77 |

Adrian Kemp

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 02 December 2019

| By: /s/
Adrian Kemp |
| --- |
| Name:
Adrian Kemp |
| Title:
Company Secretary |

page break